Clinical trials: Chronic Obstructive Pulmonary Disease Severe
Chronic Respiratory Failure
Telemedicine for Patients With Chronic Respiratory Insufficiency
In unstable patients needing oxygen and/or home mechanical ventilation, a nurse-centred TM programme (supported by continuous availability of a call centre and a pulsed oxygen system) is cost/effective saving health care…
- Trial name
- NCT00563745
- Testing
- telemedicine program
- Where
- Italy
- Volunteers
- 240 people
- Sponsor
- Michele Vitacca
COPD
Tiotropium/Salmeterol/Fluticasone Fixed Dose Combination Tratment Via Discair vs Tiotropium Via Handihaler + Salmeterol/Fluticasone Via Diskus Free Combination Treatment
The overall objective is to asses the bronchodilator effect of Tiotropium/Salmeterol/Fluticasone combination delivered via Discair® twice daily as compared with original products Seretide Diskus 500 mcg Inhalation Powder twice…
- Trial name
- NCT03395002
- Testing
- Tiotropium/Salmeterol/Fluticasone 9/50/500 mcg Inhalation Powder, Tiotropium 18 mcg Inhalation Powder, Salmeterol/Fluticasone 50/500 mcg Inhalation Powder
- Where
- 2 sites in Turkey (Türkiye)
- Volunteers
- 58 people
- Sponsor
- Neutec Ar-Ge San ve Tic A.Ş
Pain, Constipation
A Study to Demonstrate Improvement in Symptoms of Constipation in Subjects That Require Around-the-clock Opioid Pain Killer Therapy
The primary research objective is to demonstrate that subjects taking OXN PR have improvement in symptoms of constipation as measured by the Bowel Function Index (BFI) compared to subjects taking OxyPR tablets alone with cancer…
- Trial name
- NCT01438567
- Testing
- oxycodone/naloxone prolonged release (OXN PR) tablets, oxycodone prolonged release (OxyPR) tablets
- Where
- United Kingdom
- Volunteers
- 270 people
- Sponsor
- Mundipharma Research GmbH & Co KG
COPD Exacerbation
Oral Prednisolone in Severe Acute Exacerbation of Chronic Obstructive Pulmonary Disease (COPD)
Evaluation of systematic administration of oral prednisolone (1mg/Kg/day) as an add on therapy in Chronic Obstructive Pulmonary Disease (COPD) patients admitted to intensive care unit (ICU) for severe exacerbation of COPD.
- Trial name
- NCT01353235
- Testing
- Prednisolone, usual care
- Where
- Tunisia
- Volunteers
- 317 people
- Sponsor
- Fekri Abroug
Chronic Obstructive Pulmonary Disease (COPD)
A 12-week Treatment, Multi-center, Randomized, Double-blind, Parallel-group, Placebo and Active Controlled Study to Assess the Efficacy, Safety, and Tolerability of Indacaterol Maleate / Glycopyrronium Bromide in COPD Patients With Moderate to Severe Airflow Limitation
This study will assess the efficacy, safety and tolerability of indacaterol maleate/glycopyrronium bromide in patients with moderate to severe airflow limitation.
- Trial name
- NCT01712516
- Testing
- QVA149, QAB149, NVA237
- Where
- 95 sites in United States, Colombia and 7 more
- Volunteers
- 1,001 people
- Sponsor
- Novartis Pharmaceuticals
Chronic Obstructive Pulmonary Disease
PT003 MDI Dose Confirmation Study
The primary objective of this study is to demonstrate efficacy of PT003 MDI relative to its individual components (PT001 MDI and PT005 MDI) in patients with moderate to severe chronic obstructive pulmonary disease (COPD).
- Trial name
- NCT01349816
- Testing
- PT003, PT001, PT005
- Where
- 13 sites in United States
- Volunteers
- 185 people
- Sponsor
- Pearl Therapeutics, Inc.
Chronic Obstructive Pulmonary Disease
Acute Effect of Aclidinium on Hyperinflation and Ventilation Inhomogeneity in Severe COPD Patients
Chronic Obstructive Pulmonary Disease (COPD) is characterized by lung hyperinflation and flow limitation. These physiopathological modifications are secondary to loss of elastic recoil and bronchial obstruction due to emphysema.
- Trial name
- NCT02181023
- Testing
- Aclidinium Bromide, Glycopyrronium Bromide
- Where
- Italy
- Volunteers
- 37 people
- Sponsor
- University of Milan
Chronic Obstructive Pulmonary Disease
PT005 MDI Dose Ranging Versus Foradil Aerolizer Study
The purpose of this study is to evaluate the safety and efficacy of inhaled PT005 MDI compared to placebo and Foradil Aerolizer in patients with moderate to severe chronic obstructive pulmonary disease (COPD).
- Trial name
- NCT01349868
- Testing
- PT005 MDI, Formoterol Fumarate 12 μg (Foradil® Aerolizer®), Formoterol Fumarate 24 μg (Foradil® Aerolizer®)
- Where
- 3 sites in United States
- Volunteers
- 50 people
- Sponsor
- Pearl Therapeutics, Inc.
Pulmonary Disease, Chronic Obstructive
ScreenFlow: Strategy for Finding Cases of Moderate-to-Severe COPD
ScreenFlow is a chronic obstructive pulmonary disease (COPD) screening tool currently being studied and iteratively developed that incorporates a questionnaire administered on a tablet and data from a digital peak flow meter to…
- Trial name
- NCT02753556
- Volunteers
- 399 people, healthy volunteers welcome
- Sponsor
- Dimagi Inc.
Chronic Obstructive Pulmonary Disease
Efficacy, Safety, and Tolerability of Aclidinium Bromide in the Treatment of Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) (LAS-MD-38)
The purpose of this study is to evaluate the efficacy, safety and tolerability of aclidinium bromide doses compared with placebo in the treatment of moderate to severe, stable chronic obstructive pulmonary disease.
- Trial name
- LAS-MD-38 (NCT01045161)
- Testing
- Aclidinium bromide
- Where
- 112 sites in United States, Canada
- Volunteers
- 544 people
- Sponsor
- AstraZeneca
Chronic Obstructive Pulmonary Disease: COPD
Swiss studY for the Treatment of COPD Patients With the Free combiNation of indacatERol and GlYcopyrroniumbromide.
The study purpose is to evaluate the effect of QAB149 NVA237 vs. QAB149 on static lung hyperinflation.
- Trial name
- SYNERGY (NCT01699685)
- Testing
- QAB149, NVA237
- Where
- 11 sites in Switzerland
- Volunteers
- 79 people
- Sponsor
- Novartis Pharmaceuticals
Major Depressive Disorder, Recurrent, Unspecified
Deep Brain Stimulation of Nucleus Accumbens for Chronic and Resistant Major Depressive Disorder
Depression is a common, recurrent and disabling disorder. Among patients with a chronic course of the disease, 20 to 30% are resistant to antidepressant medications.
- Trial name
- PRESTHYM (NCT01569711)
- Testing
- Deep brain stimulation of nucleus accumbens
- Where
- 10 sites in France
- Volunteers
- 6 people
- Sponsor
- Rennes University Hospital
Chronic Obstructive Pulmonary Disease
Study to Evaluate the Safety and Dose-Range of Navarixin (SCH 527123, MK-7123) in Participants With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) (MK-7123-012)
This is a two-part study conducted at multiple centers, of navarixin (SCH 527123, MK-7123) in participants with moderate to severe chronic obstructive pulmonary disease (COPD).
- Trial name
- NCT00441701
- Testing
- Navarixin 1 mg, Navarixin 10 mg, Rescue medication
- Volunteers
- 99 people
- Sponsor
- Merck Sharp & Dohme LLC
COPD
CO2-Patterns During Hyperoxia and Physical Exercise in COPD
The aim of the study is to investigate a possible correlation between the change in PCO2 during a hyperoxia-test and the change in PCO2 during walking in people with COPD
- Trial name
- NCT04955561
- Testing
- Oxygen therapy, Medical Air, 10L/min O2
- Where
- Germany
- Volunteers
- 55 people
- Sponsor
- Schön Klinik Berchtesgadener Land
Chronic Obstructive Pulmonary Disease
A Phase 3 Trial to Evaluate the Safety and Efficacy of Ensifentrine in Patients With COPD
The purpose of this study is to determine if ensifentrine is safe and effective for the treatment of patients with moderate to severe Chronic Obstructive Pulmonary Disease (COPD).
- Trial name
- NCT04542057
- Testing
- Ensifentrine
- Where
- 130 sites in United States, Belgium and 8 more
- Volunteers
- 790 people
- Sponsor
- Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA
Chronic Obstructive Pulmonary Disease
Study to Evaluate the Efficacy, Safety and Pharmacokinetics of PT001, PT003, and PT005 Following Chronic Dosing (7 Days) in Patients With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD)
The purpose of this study is to evaluate, after 1 week of dosing, the efficacy and safety of PT003 compared with its individual components (PT001 and PT005), placebo and two active comparators to demonstrate superiority of the…
- Trial name
- NCT01085045
- Testing
- PT003 MDI, PT005 MDI, Tiotropium bromide 18 μg (Spiriva Handihaler®)
- Where
- 16 sites in United States, Australia and 1 more
- Volunteers
- 118 people
- Sponsor
- Pearl Therapeutics, Inc.
Severe Mental Disorder, Smoking Cessation
Tobacco Intensive Motivational and Estimate Risk
Randomized, open label, prospective study with a 12-month follow-up period. The primary objective evaluates the effectiveness of an intensive anti-smoking programme that informs patients of their individual risk of lung damages…
- Conditions
- Severe Mental Disorder, Smoking Cessation, COPD
- Trial name
- NCT03583203
- Testing
- personalized information about lung damage
- Where
- Spain
- Volunteers
- 230 people
- Sponsor
- Hospital Universitario Reina Sofia de Cordoba
Pulmonary Disease, Chronic Obstructive
Effect of Yong Chong Cao Capsule on Outcomes in Patients With Mild to Severe COPD
The aim of this study is to evaluate the effectiveness of Yong Chong Cao capsule on outcomes in patients with mild to severe Chronic Obstructive Pulmonary Disease (COPD).
- Trial name
- NCT03745261
- Testing
- Salbutamol (Ventolin®), Tiotropium Bromide (Spiriva®), Salmeterol / fluticasone (Seretide®)
- Where
- China
- Volunteers
- 240 people
- Sponsor
- Henan University of Traditional Chinese Medicine
Pulmonary Emphysema
Clinical Study to Evaluate the Exercise Capacity in Patients With Severe Emphysema Treated With Coils
The study hypothesis is that patients with homogeneous emphysema behave differently compared to heterogeneous emphysema with respect to exercise capacity.
- Trial name
- CYCLONE (NCT02879331)
- Testing
- 10 coils in upper lobes, 15 coils in upper and lower lobes, cycloergometry
- Where
- Spain
- Volunteers
- 35 people
- Sponsor
- Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz
Moderate to Severe COPD Receiving Home Exercise Training
Mobile-phone-based Home Exercise in Chronic Obstructive Pulmonary Disease
Background: Moderate-intensity exercise training improves skeletal muscle aerobic capacity and increased oxidative enzyme activity, as well as exercise tolerance in Chronic Obstructive Pulmonary Disease (COPD) patients.
- Trial name
- NCT01631019
- Testing
- Mobile-phone-based Home Exercise Training Program, Home Exercise Training Program
- Where
- Taiwan
- Volunteers
- 26 people
- Sponsor
- Chang Gung Memorial Hospital